Trial Profile

Impact of extremely early antiretroviral therapy to reduce VIral REservoir and induce functional CURE of HIV-1 infection. A pilot comparative study

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abacavir (Primary) ; Darunavir (Primary) ; Dolutegravir (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Maraviroc (Primary) ; Ritonavir (Primary) ; Tenofovir (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms VIRECURE

Most Recent Events

11 Mar 2020 Results analysing immunological changes in cell subsets in blood and rectal tissue as well as mucosal cytokine profile after initiating an intensified-5-drug ART regimen during very early PHI presented at the 27th Conference on Retroviruses and Opportunistic Infections
05 Dec 2019 Status changed from recruiting to completed.
16 Aug 2016 Planned End Date changed from 1 May 2017 to 1 Nov 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com